PHARMA MAR, S.A. «12345...» Page 5 out of 18 from 01/07/1988 to 27/09/2024 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 31/01/2019 08:42 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Results from Helix clinical trial with Tivanisiran for the treatment of dry eye disease Register number: 274317 28/01/2019 19:45 PHARMA MAR, S.A. Transmissions and purchases of capital undertakings Mandate to sell Pharma Mar´s stake in its subsidiary Zelnova Zeltia. Register number: 274204 Related with 223175 of 19/05/2015 (18:41) 24/01/2019 08:11 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks COMP, from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepsyre® for small-cell lung cáncer Register number: 274111 08/01/2019 17:50 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports details of the operations of the Liquidity Agreement between 01/10/2018 and 31/12/2018 Register number: 273581 11/12/2018 07:54 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks The Australian Regulatory Agency (TGA) has approved Aplidin® to treat multiple myeloma in combination with dexamethasone. Register number: 272345 14/11/2018 15:12 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks 100 patients have been already recruited in the Phase II clinical trial of lurbinectedin as a single agent in recurrent small cell lung cancer. Register number: 271525 30/10/2018 17:49 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding the third quarter 2018 results. Register number: 271036 30/10/2018 17:43 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del tercer trimestre de 2018 Register number: 271032 26/10/2018 15:29 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks IDMC recommends that the Phase III trial with Zepsyre® in relapsed small-cell lung cancer patients should continue without any changes Register number: 270927 19/10/2018 08:11 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks 300 patients have been already recruited in the Phase III clinical trial HELIX for the treatment of the signs and symptoms of dry eye disease. Register number: 270622 Page 5 out of 18 «12345...»